ASH 2022 | Using peripheral blood ctDNA-sequencing for PCNSL risk profiling
Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses a novel strategy to carry out risk profiling in primary central nervous system lymphoma (PCNSL). Biopsies may not be feasible in a number of patients and measuring circulating tumor DNA (ctDNA)-based peripheral residual disease (PRD) has shown to be a promising tool to guide treatment in patients with PCNSL. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Liqomics: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees; Galapagos: Consultancy.
